Is Juno Therapeutics (NASDAQ:JUNO) Now a ‘Buy’? Why did Standpoint Research Upgrade The Stock?

Share

Juno Therapeutics (NASDAQ:JUNO) Stock Upgrade

Standpoint Research boosted shares of Juno Therapeutics (NASDAQ:JUNO) to a solid Buy rating from the previous Hold. This rather important change in rating was revealed to investors and clients in a note today.

From a total of 6 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO) stock, 0 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that NaN of the ratings are positive. The highest target price is $78 while the lowest target price is $50. The mean of all analyst targets is $64.67 with a 28.07% above today’s ($46.96) stock price. Juno Therapeutics Inc was the topic of 9 analyst reports since July 22, 2015 according to the firm StockzIntelligence Inc. Goldman Sachs initiated shares on November 18 with “Neutral” rating. Standpoint Research initiated shares with “Buy” rating and $47.0 target share price in a report from an August 24. FBR Capital initiated JUNO stock in a recent report from August 18 with “Outperform” rating.

Approximately 1.48M shares of stock traded hands or 61.31% up from the average. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 1.43% since May 12, 2015 and is downtrending. It has outperformed by 2.25% the S&P500.

The overall sentiment of institutions has decreased to 0.95 in Q2 2015. Its down 1.65, from 2.6 in 2015Q2. The ratio worsened, as 59 institutions have sold all the shares of Juno Therapeutics Inc that they owned while 25 funds have taken shares off the table. 28 funds have purchased shares for the first time while 52 added to their positions. These institutions now hold 25.57 million shares or 25.97% more than the 20.30 million shares they owned in 2015Q2.

The Fund Sound Energy Partners Inc. currently is holding shares equating to 2.12% of its total portfolio in Juno Therapeutics Inc representing a total of 25,800 shares. Another fund,Bb Biotech Ag, is holding a total of 1.31 million shares equating to 1.68% of their holdings. Additionally, Kazazian Asset Management Llc has a 13,376 share stake in Juno Therapeutics Inc which represents 0.69% of their total portfolio. The Fund, Rock Springs Capital Management Lp, based out of Maryland, has also built up a stake in the stock, which represents a total of 0.65% of their total portfolio. Finally Turner Investments L.P., a fund which is based in the state of Pennsylvania reported a total holdings of 69,680 shares.

Juno Therapeutics, Inc. is a biopharmaceutical company. The company has a market cap of $4.51 billion. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.

According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”

COMMENTS: